文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

世界卫生组织关于COVID-19疫苗上市后效果评价的临时指南摘要

Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization.
PubMed 文献 · Vaccine · 2021-06-01

Ⅲ期随机对照试验显示COVID-19疫苗对有症状疾病的效力为50%至95%,但真实世界中的效果仍不明确。世界卫生组织召集专家组制定临时指南,用于评估疫苗上市后的效果,包括研究设计、优先结局、偏倚控制与报告建议。

要点

  • Ⅲ期试验疫苗效力对有症状疾病为50%至95%
  • 上市后效果评价可补充试验未覆盖的问题
  • 需关注有效性持续时间、亚人群及变异株

核心结论

  • 上市后疫苗效果评价有助于了解真实世界中疫苗减少感染和疾病的作用,并为疫苗政策提供依据。

研究设计与样本

  • 世界卫生组织召集专家组制定COVID-19疫苗效果评价的临时最佳实践指南,本文为其摘要。

主要发现

  • Ⅲ期随机对照试验显示COVID-19疫苗对有症状疾病的主要终点效力为50%至95%。
  • 试验随访时间短、纳入标准严格、出现关注变异株及流行病学变化,导致疫苗性能许多问题未解答。

关键数值与推荐

  • 上市后效果评价需评估有效性持续时间、关键亚人群(如高龄或免疫受损者)、对重症和死亡的保护、对新兴关注变异株的效果及不同接种方案。

临床怎么用

  • 利用现有监测平台开展上市后效果评价,评估不同研究设计、优先结局、潜在偏倚并规范报告结果。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phase 3 randomized-controlled trials have provided promising results of COVID-19 vaccine efficacy, ranging from 50 to 95% against symptomatic disease as the primary endpoints, resulting in emergency use authorization/listing for several vaccines. However, given the short duration of follow-up during the clinical trials, strict eligibility criteria, emerging variants of concern, and the changing epidemiology of the pandemic, many questions still remain unanswered regarding vaccine performance. Post-introduction vaccine effectiveness evaluations can help us to understand the vaccine's effect on reducing infection and disease when used in real-world conditions. They can also address important questions that were either not studied or were incompletely studied in the trials and that will inform evolving vaccine policy, including assessment of the duration of effectiveness; effectiveness in key subpopulations, such as the very old or immunocompromised; against severe disease and death due to COVID-19; against emerging SARS-CoV-2 variants of concern; and with different vaccination schedules, such as number of doses and varying dosing intervals. WHO convened an expert panel to develop interim best practice guidance for COVID-19 vaccine effectiveness evaluations. We present a summary of the interim guidance, including discussion of different study designs, priority outcomes to evaluate, potential biases, existing surveillance platforms that can be used, and recommendations for reporting results.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. 2021. PMID: 34119350. doi:10.1016/j.vaccine.2021.05.099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。